Related Experiment Video
Updated: Oct 17, 2025
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
Can gut microbes predict efficacy and toxicity of combined immune checkpoint blockade?
Khiem C Lam1, Romina S Goldszmid1
1Inflammatory Cell Dynamics Section, Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Abstract:
A recent report in Nature Medicine pinpoints a role for gut microbiota in response and toxicity to combined immune checkpoint blockade targeting CTLA-4 and PD-1. This emergent study provides insights that can be used to leverage microbiota in the design of anticancer therapies to mitigate toxicity while enhancing efficacy.
Insights
Gut bacteria play a key role in the effectiveness and side effects of combined immune checkpoint blockade therapies. Understanding this connection can help improve cancer treatments by reducing toxicity and increasing efficacy.
Area of Science:
- Immunology
- Microbiology
- Oncology
Background:
- Immune checkpoint blockade (ICB) therapies targeting CTLA-4 and PD-1 have revolutionized cancer treatment.
- However, response and toxicity vary significantly among patients.
- The role of the gut microbiota in modulating ICB efficacy and toxicity remains an active area of investigation.
Purpose of the Study:
- To investigate the influence of gut microbiota composition on the response and toxicity of combined CTLA-4 and PD-1 blockade.
- To identify specific microbial signatures associated with favorable or adverse outcomes.
- To explore potential strategies for manipulating the gut microbiota to enhance ICB therapy.
Main Methods:
- Analysis of gut microbial communities in patients undergoing combined ICB therapy.
- Correlation of microbial diversity and composition with clinical response and immune-related adverse events.
- Experimental models to confirm the functional role of specific bacteria in ICB response and toxicity.
Main Results:
- Specific gut microbial profiles were associated with differential responses to combined ICB therapy.
- Certain bacterial species were linked to increased efficacy, while others correlated with heightened toxicity.
- Modulation of the gut microbiota composition showed potential to influence treatment outcomes.
Conclusions:
- Gut microbiota composition is a critical determinant of response and toxicity in patients treated with combined CTLA-4 and PD-1 blockade.
- Targeting the gut microbiota represents a promising strategy to optimize ICB therapy.
- Future research should focus on leveraging microbiota-based interventions to improve anticancer treatment efficacy and patient safety.
